Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Clin Pharmacol Ther ; 111(3): 579-584, 2022 03.
Artículo en Inglés | MEDLINE | ID: covidwho-1396859

RESUMEN

Patients with coronavirus disease 2019 (COVID-19) may experience a cytokine storm with elevated interleukin-6 (IL-6) levels in response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). IL-6 suppresses hepatic enzymes, including CYP3A; however, the effect on drug exposure and drug-drug interaction magnitudes of the cytokine storm and resulting elevated IL-6 levels have not been characterized in patients with COVID-19. We used physiologically-based pharmacokinetic (PBPK) modeling to simulate the effect of inflammation on the pharmacokinetics of CYP3A metabolized drugs. A PBPK model was developed for lopinavir boosted with ritonavir (LPV/r), using clinically observed data from people living with HIV (PLWH). The inhibition of CYPs by IL-6 was implemented by a semimechanistic suppression model and verified against clinical data from patients with COVID-19, treated with LPV/r. Subsequently, the verified model was used to simulate the effect of various clinically observed IL-6 levels on the exposure of LPV/r and midazolam, a CYP3A model drug. Clinically observed LPV/r concentrations in PLWH and patients with COVID-19 were predicted within the 95% confidence interval of the simulation results, demonstrating its predictive capability. Simulations indicated a twofold higher LPV exposure in patients with COVID-19 compared with PLWH, whereas ritonavir exposure was predicted to be comparable. Varying IL-6 levels under COVID-19 had only a marginal effect on LPV/r pharmacokinetics according to our model. Simulations showed that a cytokine storm increased the exposure of the CYP3A paradigm substrate midazolam by 40%. Our simulations suggest that CYP3A metabolism is altered in patients with COVID-19 having increased cytokine release. Caution is required when prescribing narrow therapeutic index drugs particularly in the presence of strong CYP3A inhibitors.


Asunto(s)
COVID-19/complicaciones , Citocromo P-450 CYP3A/metabolismo , Síndrome de Liberación de Citoquinas/virología , Lopinavir/farmacocinética , Midazolam/farmacocinética , Ritonavir/farmacocinética , Adulto , COVID-19/metabolismo , Citocromo P-450 CYP3A/farmacocinética , Inhibidores del Citocromo P-450 CYP3A/farmacocinética , Síndrome de Liberación de Citoquinas/tratamiento farmacológico , Síndrome de Liberación de Citoquinas/metabolismo , Citocinas/metabolismo , Humanos , Tasa de Depuración Metabólica/efectos de los fármacos , Persona de Mediana Edad , Modelos Biológicos , Tratamiento Farmacológico de COVID-19
2.
J Zhejiang Univ Sci B ; 22(7): 599-602, 2021 Jul 15.
Artículo en Inglés | MEDLINE | ID: covidwho-1315902

RESUMEN

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has occasioned worldwide alarm. Globally, the number of reported confirmed cases has exceeded 84.3 million as of this writing (January 2, 2021). Since there are no targeted therapies for COVID-19, the current focus is the repurposing of drugs approved for other uses. In some clinical trials, antiviral drugs such as remdesivir (Grein et al., 2020), lopinavir/ritonavir (LPV/r) (Cao et al., 2020), chloroquine (Gao et al., 2020), hydroxychloroquine (Gautret et al., 2020), arbidol (Wang et al., 2020), and favipiravir (Cai et al., 2020b) have shown efficacy in COVID-19 patients. LPV/r combined with arbidol, which is the basic regimen in some regional hospitals in China including Zhejiiang Province, has shown antiviral effects in COVID-19 patients (Guo et al., 2020; Xu et al., 2020). A retrospective cohort study also reported that this combination therapy showed better efficacy than LPV/r alone for the treatment of COVID-19 patients (Deng et al., 2020).


Asunto(s)
Tratamiento Farmacológico de COVID-19 , Indoles/administración & dosificación , Lopinavir/administración & dosificación , Ritonavir/administración & dosificación , SARS-CoV-2 , Animales , Interacciones Farmacológicas , Quimioterapia Combinada , Femenino , Indoles/farmacocinética , Lopinavir/farmacocinética , Masculino , Ratas , Estudios Retrospectivos , Ritonavir/farmacocinética
3.
Crit Rev Anal Chem ; 52(8): 1846-1862, 2022.
Artículo en Inglés | MEDLINE | ID: covidwho-1240847

RESUMEN

Lopinavir/ritonavir is a potent coformulation of protease inhibitors used against HIV infection. Lopinavir is the main responsible for viral load suppression, whereas ritonavir is a pharmacokinetic enhancer. Both of them have recently gained relevance as candidate drugs against severe coronavirus disease (COVID-19). However, significant beneficial effects were not observed in randomized clinical trials. This review summarizes the main physical-chemical, pharmacodynamic, and pharmacokinetic properties of ritonavir and lopinavir, along with the analytical methodologies applied for biological matrices, pharmaceutical formulations, and stability studies. The work also aimed to provide a comprehensive impurity profile for the combined formulation. Several analytical methods in four different pharmacopeias and 37 articles in literature were evaluated and summarized. Chromatographic methods for these drugs frequently use C8 or C18 stationary phases with acetonitrile and phosphate buffer (with ultraviolet detection) or acetate buffer (with tandem mass spectrometry detection) as the mobile phase. Official compendia methods show disadvantages as extended total run time and complex mobile phases. HPLC tandem-mass spectrometry provided high sensitivity in methodologies applied for human plasma and serum samples, supporting the therapeutic drug monitoring in HIV patients. Ritonavir and lopinavir major degradation products arise in alkaline and acidic environments, respectively. Other non-chromatographic methods were also summarized. Establishing the impurity profile for the combined formulation is challenging due to a large number of impurities reported. Easier and faster analytical methods for impurity assessment are still needed.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , Infecciones por VIH , Inhibidores de la Proteasa del VIH , Humanos , Lopinavir/farmacocinética , Lopinavir/uso terapéutico , Ritonavir/efectos adversos , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inducido químicamente , Inhibidores de la Proteasa del VIH/efectos adversos , Composición de Medicamentos
4.
Food Chem Toxicol ; 149: 111998, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: covidwho-1139497

RESUMEN

Corona Virus Disease 2019 (COVID-19) has spread all over the world and brings significantly negative effects on human health. To fight against COVID-19 in a more efficient way, drug-drug or drug-herb combinations are frequently used in clinical settings. The concomitant use of multiple medications may trigger clinically relevant drug/herb-drug interactions. This study aims to assay the inhibitory potentials of Qingfei Paidu decoction (QPD, a Chinese medicine compound formula recommended for combating COVID-19 in China) against human drug-metabolizing enzymes and to assess the pharmacokinetic interactions in vivo. The results demonstrated that QPD dose-dependently inhibited CYPs1A, 2A6, 2C8, 2C9, 2C19, 2D6 and 2E1 but inhibited CYP3A in a time- and NADPH-dependent manner. In vivo test showed that QPD prolonged the half-life of lopinavir (a CYP3A substrate-drug) by 1.40-fold and increased the AUC of lopinavir by 2.04-fold, when QPD (6 g/kg) was co-administrated with lopinavir (160 mg/kg) to rats. Further investigation revealed that Fructus Aurantii Immaturus (Zhishi) in QPD caused significant loss of CYP3A activity in NADPH-generating system. Collectively, our findings revealed that QPD potently inactivated CYP3A and significantly modulated the pharmacokinetics of CYP3A substrate-drugs, which would be very helpful for the patients and clinicians to avoid potential drug-interaction risks in COVID-19 treatment.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , Citocromo P-450 CYP3A/metabolismo , Medicamentos Herbarios Chinos/farmacología , Interacciones de Hierba-Droga , Animales , Área Bajo la Curva , China , Medicamentos Herbarios Chinos/uso terapéutico , Lopinavir/farmacocinética , Masculino , Microsomas Hepáticos , NADP/metabolismo , Fitoterapia , Ratas Sprague-Dawley , SARS-CoV-2
5.
Eur J Clin Pharmacol ; 77(3): 389-397, 2021 Mar.
Artículo en Inglés | MEDLINE | ID: covidwho-1064451

RESUMEN

OBJECTIVE: To develop a population pharmacokinetic model for lopinavir boosted by ritonavir in coronavirus disease 2019 (Covid-19) patients. METHODS: Concentrations of lopinavir/ritonavir were assayed by an accredited LC-MS/MS method. The population pharmacokinetics of lopinavir was described using non-linear mixed-effects modeling (NONMEM version 7.4). After determination of the base model that better described the data set, the influence of covariates (age, body weight, height, body mass index (BMI), gender, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), C reactive protein (CRP), and trough ritonavir concentrations) was tested on the model. RESULTS: From 13 hospitalized patients (4 females, 9 males, age = 64 ± 16 years), 70 lopinavir/ritonavir plasma concentrations were available for analysis. The data were best described by a one-compartment model with a first-order input (KA). Among the covariates tested on the PK parameters, only the ritonavir trough concentrations had a significant effect on CL/F and improved the fit. Model-based simulations with the final parameter estimates under a regimen lopinavir/ritonavir 400/100 mg b.i.d. showed a high variability with median concentration between 20 and 30 mg/L (Cmin/Cmax) and the 90% prediction intervals within the range 1-100 mg/L. CONCLUSION: According to the estimated 50% effective concentration of lopinavir against SARS-CoV-2 virus in Vero E6 cells (16.7 mg/L), our model showed that at steady state, a dose of 400 mg b.i.d. led to 40% of patients below the minimum effective concentration while a dose of 1200 mg b.i.d. will reduce this proportion to 22%.


Asunto(s)
Antivirales/farmacocinética , COVID-19/metabolismo , Lopinavir/farmacocinética , Ritonavir/farmacocinética , Anciano , Anciano de 80 o más Años , Animales , Antivirales/uso terapéutico , Índice de Masa Corporal , Chlorocebus aethiops , Simulación por Computador , Combinación de Medicamentos , Femenino , Humanos , Lopinavir/uso terapéutico , Masculino , Persona de Mediana Edad , Modelos Biológicos , Población , Ritonavir/uso terapéutico , Análisis de Supervivencia , Distribución Tisular , Células Vero , Tratamiento Farmacológico de COVID-19
6.
Clin Pharmacol Ther ; 109(4): 1030-1033, 2021 04.
Artículo en Inglés | MEDLINE | ID: covidwho-1064339

RESUMEN

Boffito et al. recalled the critical importance to correctly interpret protein binding. Changes of lopinavir pharmacokinetics in coronavirus disease 2019 (COVID-19) are a perfect illustration. Indeed, several studies described that total lopinavir plasma concentrations were considerably higher in patients with severe COVID-19 than those reported in patients with HIV. These findings have led to a reduction of the dose of lopinavir in some patients, hypothesizing an inhibitory effect of inflammation on lopinavir metabolism. Unfortunately, changes in plasma protein binding were never investigated. We performed a retrospective cohort study. Data were collected from the medical records of patients hospitalized for COVID-19 treated with lopinavir/ritonavir in intensive care units or infectious disease departments of Toulouse University Hospital (France). Total and unbound concentrations of lopinavir, C reactive protein, albumin, and alpha-1-acid glycoprotein (AAG) levels were measured during routine care on the same samples. In patients with COVID-19, increased total lopinavir concentration is the result of an increased AAG-bound lopinavir concentration, whereas the unbound concentration remains constant, and insufficient to reduce the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) viral load. Although international guidelines have recently recommended against using lopinavir/ritonavir to treat severe COVID-19, the description of lopinavir pharmacokinetics changes in COVID-19 is a textbook case of the high risk of misinterpretation of a total drug exposure when changes in protein binding are not taken into consideration.


Asunto(s)
Antivirales/farmacocinética , Tratamiento Farmacológico de COVID-19 , Lopinavir/farmacocinética , Plasma/fisiología , Unión Proteica/fisiología , Anciano , Albúminas/metabolismo , Antivirales/uso terapéutico , Proteína C-Reactiva/metabolismo , Femenino , Glicoproteínas/metabolismo , Humanos , Lopinavir/uso terapéutico , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , SARS-CoV-2 , Carga Viral
8.
Clin Pharmacol Ther ; 108(6): 1176-1184, 2020 12.
Artículo en Inglés | MEDLINE | ID: covidwho-696806

RESUMEN

Lopinavir/ritonavir, originally developed for treating HIV, is currently undergoing clinical studies for treating the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although recent reports suggest that lopinavir exhibits in vitro efficacy against SARS-CoV-2, it is a highly protein-bound drug and it remains unknown if it reaches adequate in vivo unbound (free) concentrations in lung tissue. We built a physiologically-based pharmacokinetic model of lopinavir/ritonavir in white and Chinese populations. Our aim was to perform pharmacokinetic/pharmacodynamic correlations by comparing simulated free plasma and lung concentration values achieved using different dosing regimens of lopinavir/ritonavir with unbound half-maximal effective concentration (EC50,unbound ) and unbound effective concentration 90% values of lopinavir against SARS-CoV-2. The model was validated against multiple observed clinical datasets for single and repeated dosing of lopinavir/ritonavir. Predicted pharmacokinetic parameters, such as the maximum plasma concentration, area under the plasma concentration-time profile, oral clearance, half-life, and minimum plasma concentration at steady-state were within two-fold of clinical values for both populations. Using the current lopinavir/ritonavir regimen of 400/100 mg twice daily, lopinavir does not achieve sufficient free lung concentrations for efficacy against SARS-CoV-2. Although the Chinese population reaches greater plasma and lung concentrations as compared with whites, our simulations suggest that a significant dose increase from the current clinically used dosing regimen is necessary to reach the EC50,unbound value for both populations. Based on safety data, higher doses would likely lead to QT prolongation and gastrointestinal disorders (nausea, vomiting, and diarrhea), thus, any dose adjustment must be carefully weighed alongside these safety concerns.


Asunto(s)
Antivirales/farmacocinética , Tratamiento Farmacológico de COVID-19 , Lopinavir/farmacocinética , Ritonavir/farmacocinética , Área Bajo la Curva , Pueblo Asiatico , Relación Dosis-Respuesta a Droga , Infecciones por VIH/tratamiento farmacológico , Semivida , Humanos , Lopinavir/farmacología , Pulmón/metabolismo , Tasa de Depuración Metabólica , Modelos Biológicos , Ritonavir/farmacología , SARS-CoV-2 , Población Blanca
9.
Antimicrob Agents Chemother ; 64(9)2020 08 20.
Artículo en Inglés | MEDLINE | ID: covidwho-639066

RESUMEN

Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine release, which can downregulate the expression of metabolizing enzymes. This cascade affects drug concentrations in the plasma. We investigated the association between lopinavir (LPV) and hydroxychloroquine (HCQ) plasma concentrations and the levels of the acute-phase inflammation marker C-reactive protein (CRP). LPV plasma concentrations in 92 patients hospitalized at our institution were prospectively collected. Lopinavir-ritonavir was administered every 12 hours, 800/200 mg on day 1 and 400/100 mg on day 2 until day 5 or 7. HCQ was given at 800 mg, followed by 400 mg after 6, 24, and 48 h. Hematological, liver, kidney, and inflammation laboratory values were analyzed on the day of drug level determination. The median age of study participants was 59 (range, 24 to 85) years, and 71% were male. The median durations from symptom onset to hospitalization and treatment initiation were 7 days (interquartile range [IQR], 4 to 10) and 8 days (IQR, 5 to 10), respectively. The median LPV trough concentration on day 3 of treatment was 26.5 µg/ml (IQR, 18.9 to 31.5). LPV plasma concentrations positively correlated with CRP values (r = 0.37, P < 0.001) and were significantly lower when tocilizumab was preadministered. No correlation was found between HCQ concentrations and CRP values. High LPV plasma concentrations were observed in COVID-19 patients. The ratio of calculated unbound drug fraction to published SARS-CoV-2 50% effective concentrations (EC50) indicated insufficient LPV concentrations in the lung. CRP values significantly correlated with LPV but not HCQ plasma concentrations, implying inhibition of cytochrome P450 3A4 (CYP3A4) metabolism by inflammation.


Asunto(s)
Antivirales/farmacocinética , Betacoronavirus/efectos de los fármacos , Infecciones por Coronavirus/tratamiento farmacológico , Síndrome de Liberación de Citoquinas/tratamiento farmacológico , Hidroxicloroquina/farmacocinética , Lopinavir/farmacocinética , Neumonía Viral/tratamiento farmacológico , Ritonavir/farmacocinética , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antivirales/sangre , Antivirales/farmacología , Betacoronavirus/inmunología , Betacoronavirus/patogenicidad , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , COVID-19 , Infecciones por Coronavirus/inmunología , Infecciones por Coronavirus/mortalidad , Infecciones por Coronavirus/virología , Síndrome de Liberación de Citoquinas/inmunología , Síndrome de Liberación de Citoquinas/mortalidad , Síndrome de Liberación de Citoquinas/virología , Esquema de Medicación , Combinación de Medicamentos , Femenino , Hospitales Universitarios , Humanos , Hidroxicloroquina/sangre , Hidroxicloroquina/farmacología , Tiempo de Internación/estadística & datos numéricos , Lopinavir/sangre , Lopinavir/farmacología , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/inmunología , Neumonía Viral/mortalidad , Neumonía Viral/virología , Estudios Retrospectivos , Ritonavir/sangre , Ritonavir/farmacología , SARS-CoV-2 , Índice de Severidad de la Enfermedad , Análisis de Supervivencia
10.
Am J Transplant ; 20(7): 1896-1901, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: covidwho-125541

RESUMEN

The current coronavirus disease 2019 (COVID-19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients. We report on a case of a 35-year-old renal transplant recipient who suffered from a severe COVID-19 pneumonia. The clinical course was complicated by extreme overexposure to the mammalian target of rapamycin inhibitor everolimus, following coadministration of chloroquine and lopinavir/ritonavir therapy. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence-based COVID-19 therapy and concurrent pressure for exploration of experimental pharmacological treatment options. However, the risk-benefit balance of experimental or off-label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID-19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case report, we aimed to achieve increased awareness and improved management of drug-drug interactions associated with the various treatment options for COVID-19 in renal transplant patients.


Asunto(s)
Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/terapia , Everolimus/farmacocinética , Fallo Renal Crónico/complicaciones , Trasplante de Riñón , Neumonía Viral/complicaciones , Neumonía Viral/terapia , Receptores de Trasplantes , Adulto , Antivirales/administración & dosificación , Antivirales/farmacocinética , Betacoronavirus , COVID-19 , Cloroquina/administración & dosificación , Cloroquina/farmacocinética , Combinación de Medicamentos , Interacciones Farmacológicas , Everolimus/administración & dosificación , Humanos , Huésped Inmunocomprometido , Inmunosupresores/administración & dosificación , Inmunosupresores/farmacocinética , Fallo Renal Crónico/cirugía , Lopinavir/administración & dosificación , Lopinavir/farmacocinética , Masculino , Países Bajos , Pandemias , Radiografía Torácica , Ritonavir/administración & dosificación , Ritonavir/farmacocinética , SARS-CoV-2 , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA